| Autor: |
Afrin LB; AIM Center for Personalized Medicine, Purchase, New York, NY 10577, USA., Dempsey TT; AIM Center for Personalized Medicine, Purchase, New York, NY 10577, USA., Weinstock LB; Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Vaccines [Vaccines (Basel)] 2022 Jan 16; Vol. 10 (1). Date of Electronic Publication: 2022 Jan 16. |
| DOI: |
10.3390/vaccines10010127 |
| Abstrakt: |
For nearly a decade, case reports and series have emerged regarding dysautonomias-particularly postural orthostatic tachycardia syndrome (POTS)-presenting soon after vaccination against human papilloma virus (HPV). We too have observed a number of such cases (all following vaccination with the Gardasil product), and have found several to have detectable mast cell activation syndrome (MCAS) as well as histories suggesting that MCAS was likely present long before vaccination. We detail 11 such cases here, posing a hypothesis that HPV vaccination (at least with the Gardasil product) may have triggered or exacerbated MCAS in teenagers previously not recognized to have it. Only recently recognized, MCAS is being increasingly appreciated as a prevalent and chronic multisystem disorder, often emerging early in life and presenting with inflammatory ± allergic phenomena following from known mast cell (MC) mediator effects. There is rising recognition, too, of associations of MCAS with central and peripheral neuropathic disorders, including autonomic disorders such as POTS. Given the recognized potential for many antigens to trigger a major and permanent escalation of baseline MC misbehavior in a given MCAS patient, we hypothesize that in our patients described herein, vaccination with Gardasil may have caused pre-existing (but not yet clinically recognized) MCAS to worsen to a clinically significantly degree, with the emergence of POTS and other issues. The recognition and management of MCAS prior to vaccinations in general may be a strategy worth investigating for reducing adverse events following HPV vaccinations and perhaps even other types of vaccinations. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
